Abstract 359P
Background
In particular, cancer patients with minor children encounter various problems, including family, parenting, employment, and economic burdens. This study aimed to examine the economic burden among cancer patients with minor children.
Methods
This was a sub-analysis of a cross-sectional web-based survey. Cancer patients with minor children were recruited from an online community and asked to answer a questionnaire.The proportion of subjects experiencing economic burden, and factors associated with economic burden were analyzed.
Results
A total of 368 subjects were eligible [19% male, mean age (SD): 43.0 years (5.8)]. The most common primary cancer site was breast (34%), followed by the colorectal region (12%), and gynecological organs (11%). Among the subjects, 127 (34%) experiencedeconomic burden. Univariate analyses showed that advanced stage (38% in subjects experiencing economic burden vs. 22% in subjects not experiencingeconomic burden, p = 0.002), presence of metastases (51% vs. 35%, p = 0.004), cancer recurrence (24% vs. 14%, p = 0.032), using anti-tumor drugs (47% vs. 33%, p = 0.010), having a full-time job (24% vs. 48%, p < 0.001), change of work situation (76% vs. 44%, p < 0.001), and decrease of income (76% vs. 38%, p < 0.001) were associated with patients experiencingeconomic burden.
Conclusions
The present study showed that advanced stage, anti-tumor treatment, and work situation were associated with economic burden among cancer patients with minor children.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Cancer Center.
Funding
Takeda Science Foundation.
Disclosure
K. Kosugi: Honoraria (self): Mundipharma. D. Fujisawa: Honoraria (self): Pfeizer, Mochida, Tanabe-Mitsubishi, Shionogi, Meiji Pharma, MSD. T. Kawaguchi: Honoraria (self): Chugai. K. Izumi: Full / Part-time employment: Medilead Inc. J. Takehana: Full / Part-time employment: Medilead Inc. Y. Matsumoto: Honoraria (self): Kyowa Kirin; Honoraria (self): Shionogi; Honoraria (self): Terumo; Honoraria (self): Meiji Seika Pharma; Honoraria (self): Hisamitsu Pharmaceutical; Honoraria (self): Eisai; Honoraria (self): Pfizer; Honoraria (self): AstraZeneca; Honoraria (self): Mundipharma; Honoraria (self): Daiichi-Sankyo. All other authors have declared no conflicts of interest.
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract